Obesity is a prevalent disorder that often leads to diabetes and cardiovascular disease. We have recently found that transgenic mice engineered to have brown fat deficiency become markedly obese, suggesting that brown fat protects against the development of obesity. We now seek to better understand the mechanisms by which brown fat is regulated, specifically the role of beta/3-adrenergic receptors (beta/3-ARs). The activity of brown fat is controlled predominantly by the sympathetic nervous system. Norepinephrine, released from sympathetic nerves, activates brown fat by binding to adrenergic receptors. Recently, brown fat has been found to possess a highly specialized beta-adrenergic receptor (beta-AR), termed the beta/3-AR. This receptor is the most abundant beta-AR in adipose tissue and is decreased by 70-98% in genetic models of obesity. Pharmaceutical companies have synthesized """"""""atypical"""""""" beta-AR agonists which stimulate beta/3-ARs, and these compounds hold promise as anti-obesity, anti-diabetes agents. For these reasons, there is great interest in the beta/3-AR, and the drugs which stimulate it. However, the function of beta/3-ARs in normal physiology, and the mechanisms by which atypical beta-AR agonists produce their effects, are incompletely understood. To address these issues, a genetic analysis of beta/3-AR function has been undertaken. Using homologous recombination, we have generated mice which completely lack beta/3-ARs. These animals will be used to determine the function of beta/3-ARs in normal physiology and to define the receptor through which atypical beta-AR agonists produce their many effects. By reexpressing beta/3-ARs transgenically in selected tissues of deficient mice, it will be possible to establish the sites of action for these various effects. Finally, by transgenically reconstituting beta/3-AR deficient mice with human receptors, it will be possible to determine the capacity of activated human beta/3-ARs to augment thermogenesis. Given the high specificity of this genetic approach, information obtained from these mice concerning the function of this receptor, should be definitive in nature.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK049569-03
Application #
2414889
Study Section
Nutrition Study Section (NTN)
Project Start
1995-05-30
Project End
1998-04-30
Budget Start
1997-05-01
Budget End
1998-04-30
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Vianna, Claudia R; Huntgeburth, Michael; Coppari, Roberto et al. (2006) Hypomorphic mutation of PGC-1beta causes mitochondrial dysfunction and liver insulin resistance. Cell Metab 4:453-64
Huppertz, C; Fischer, B M; Kim, Y B et al. (2001) Uncoupling protein 3 (UCP3) stimulates glucose uptake in muscle cells through a phosphoinositide 3-kinase-dependent mechanism. J Biol Chem 276:12520-9
Vidal-Puig, A J; Grujic, D; Zhang, C Y et al. (2000) Energy metabolism in uncoupling protein 3 gene knockout mice. J Biol Chem 275:16258-66
Cohen, M L; Bloomquist, W; Ito, M et al. (2000) Beta3 receptors mediate relaxation in stomach fundus whereas a fourth beta receptor mediates tachycardia in atria from transgenic beta3 receptor knockout mice. Receptors Channels 7:17-23
Hagen, T; Lowell, B B (2000) Chimeric proteins between UCP1 and UCP3: the middle third of UCP1 is necessary and sufficient for activation by fatty acids. Biochem Biophys Res Commun 276:642-8
Hagen, T; Zhang, C Y; Vianna, C R et al. (2000) Uncoupling proteins 1 and 3 are regulated differently. Biochemistry 39:5845-51
Zhang, C Y; Hagen, T; Mootha, V K et al. (1999) Assessment of uncoupling activity of uncoupling protein 3 using a yeast heterologous expression system. FEBS Lett 449:129-34
Hagen, T; Zhang, C Y; Slieker, L J et al. (1999) Assessment of uncoupling activity of the human uncoupling protein 3 short form and three mutants of the uncoupling protein gene using a yeast heterologous expression system. FEBS Lett 454:201-6
Vidal-Puig, A; Rosenbaum, M; Considine, R C et al. (1999) Effects of obesity and stable weight reduction on UCP2 and UCP3 gene expression in humans. Obes Res 7:133-40
Boss, O; Bachman, E; Vidal-Puig, A et al. (1999) Role of the beta(3)-adrenergic receptor and/or a putative beta(4)-adrenergic receptor on the expression of uncoupling proteins and peroxisome proliferator-activated receptor-gamma coactivator-1. Biochem Biophys Res Commun 261:870-6

Showing the most recent 10 out of 18 publications